With news headlines all too often reporting cases of fatal overdoses and the discovery of new psychoactive substances (NPS) on the black market, our Director of Sales for North America, Pankaj Sinha, recently attended the West Virginia Research and Innovation Symposium.
Taking place at Shepard University, the focus of the symposium was to discuss the urgent need to combat the growing opioid epidemic in America. Between 2009-2016, 106 countries and territories reported the emergence of 739 NPS to the United Nations office on Drugs and Crime (UNDOC), with 66 NPS formally notified in 2016 highlighting the important need for more research and development to understand the drug-metabolite profile in forensic toxicology.
Pankaj met with Government Officials including Senators Manchin and Capito to discuss Randox Toxicology developments, including our latest NPS tests, which detects classic designer drugs, fentanyl and opioids including sufentanil, ocfentanyl and carfentanil. Cartentanil, which is 100 times more potent than morphine and is commonly used as a general anaesthetic agent for larger animals such as elephants and is not approved for human use.
Along with our NPS range we also offer an exclusive range of ELISA tests including AH-7921, MT-45, Zaleplon and Mitragynine (also known as Kratom). All our ELISA tests provide rapid detection of drugs of abuse and metabolites in various biological specimens offering excellent cross-reactivity and unrivalled limits of detection and correlation with GC/LCMS.
With the countless possibilities for creating new compounds by making minor changes in chemical structures posing a growing challenge to legislative controls and the fact that the competency and composition of these new opioids are not known it makes it difficult to know what long term adverse effects they will have. That’s why our R&D team are dedicated to researching and developing the latest assays to meet the demands of the ever changing toxicology market.